| URL | https://www.fiercepharma.com/manufacturing/beigene |
| Source | https://www.fiercepharma.com |
| Date Published | 11/24/2021 |
| Author Name | Joseph Keenan |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | BeiGene Ltd. |
| Parent company | BeiGene |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2024 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | China |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Cancer drugs |
| Product(s) reshored | Cancer drugs |